Representatives Paul Tonko, D-New York, and Rob Gibbs, R-Ohio, have introduced H.R. 4629, the Star Ratings for Biosimilars Act, in the House. The bipartisan bill would require HHS to evaluate Medicare Advantage (MA) plans based on whether biosimilars are available to enrollees.
Representatives Paul Tonko, D-New York, and Rob Gibbs, R-Ohio, have introduced H.R. 4629, the Star Ratings for Biosimilars Act, in the House. The bipartisan bill would require HHS to evaluate Medicare Advantage (MA) plans based on whether biosimilars are available to enrollees.
Under the proposed legislation, which would amend title 18 of the Social Security Act, starting in 2021, HHS would add a new set of measures to the current 5-star rating system based on biosimilar access in Part B and, for MA plans that offer prescription drug coverage, in Part D.
The measures include assessing the following: whether a biosimilar is on the formulary in lieu of or in addition to the reference, tier placement or cost-sharing for biosimilars relative to the reference, whether and how utilization management is applied, and the percentage of enrollees prescribed biosimilars rather than references.
The bill has now been referred to the Committee on Energy and Commerce and the Committee on Ways and Means.
According to a statement by Tonko, “certain profitable dynamics in America’s health care system are blocking access to these cost saving alternatives, meaning our patients and their families are forced to pay a higher price for substantially similar medical care. My bill will highlight the existing barriers in current health plans, provide for meaningful transparency where plans fall short, and allow for reform to unlock the billions in savings for America’s patients and taxpayers."
Trade group the Biosimilars Forum praised the provisions, saying in a statement on the bill that “CMS must take this opportunity to save seniors and taxpayers money. Congressmen Tonko and Gibbs understand the importance of identifying inefficiencies in health plans that are blocking patient access and use of lower-cost biosimilars to treat some of life’s most complex illnesses. Through this measurement, it will allow for reforms that will encourage health plans to drive significant savings in health care.”
In the Senate, parallel provisions have been put forth under S.2543, or the Prescription Drug Pricing Reduction Act of 2019, sponsored by Senator Chuck Grassley, R-Iowa. The Senate bill was introduced in the Senate in September, and which has been placed on the Senate legislative calendar under general orders.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.